Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.13
+0.12 (1.50%)
Last updated: Mar 10, 2026, 3:10 PM HKT
19.56%
Market Cap 1.93B
Revenue (ttm) 1.43B
Net Income (ttm) 135.25M
Shares Out 241.52M
EPS (ttm) 0.60
PE Ratio 13.44
Forward PE n/a
Dividend 0.06 (0.74%)
Ex-Dividend Date n/a
Volume 7,000
Average Volume 90,120
Open 8.19
Previous Close 8.01
Day's Range 8.02 - 8.20
52-Week Range 5.36 - 16.29
Beta n/a
RSI 31.12
Earnings Date Mar 26, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by rad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 1,629
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2566
Full Company Profile

Financial Performance

In 2024, HKG:2566's revenue was 1.37 billion, an increase of 6.35% compared to the previous year's 1.29 billion. Earnings were 138.60 million, an increase of 15.72%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.